DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Osteoarthritic (OA) pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug developers given the persistent unmet need for more effective and safe therapies, particularly agents with a novel and distinct mechanism of action that strongly correlates with the nature of this type of pain. OA pain is predominantly treated with cost-effective generic nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics, new combinations of existing NSAIDs that attempt to mitigate side effects, and intra-articular injections are also frequently prescribed in later lines of therapy. Emerging therapies, such as biological drugs from Pfizer/Eli Lilly and Regeneron/Teva/Mitsubishi Tanabe Pharma targeting nerve growth factor (NGF), and the increasing number of patients diagnosed with OA pain due to lifestyle influences will be key drivers for growth through 2028.

Questions Answered:

How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse/misuse with opioid analgesics?

What effect will the recent launches of new analgesics such as Flexion Therapeutics’ Zilretta and Iroko’s Vivlodex continue to have on the treatment paradigm?

What will the impact of a new drug class, the anti-NGF biologics, be on the treatment landscape given their demonstrably robust efficacy tempered by lingering concerns about safety issues seen in clinical trials?

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content. Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.

Andrea S. Witt, is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology. Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her degree.

Wouter van der Pluijm is a Senior Epidemiologist at Decision Resources Group and joined in 2014. Wouter holds an in Epidemiology from the University of Michigan. Prior to joining DRG, Wouter worked for the Washtenaw County Public Health Department on the epidemiology and public health surveillance teams, studying West Nile virus, as well as depression and drug abuse in the county.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

"Niyati Khetarpal is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;